{"id":"NCT01232569","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis","officialTitle":"A Randomized, Double-blind, Parallel Group Study of Safety and the Effect on Clinical Outcome of Tocilizumab Subcutaneous (sc) Versus Placebo sc in Combination With Traditional Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2012-05","completion":"2013-11","firstPosted":"2010-11-02","resultsPosted":"2013-10-23","lastUpdate":"2015-07-29"},"enrollment":656,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Tocilizumab 162 mg","otherNames":["RoActemra","Actemra"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tocilizumab 162 mg sc","type":"EXPERIMENTAL"},{"label":"Placebo sc","type":"PLACEBO_COMPARATOR"}],"summary":"This randomized, parallel-group, placebo-controlled, multicenter study will evaluate the reduction in disease activity and the safety of tocilizumab (RoActemra/Actemra) in combination with traditional disease-modifying anti-rheumatic drugs (DMARDs) in patients with active, moderate to severe rheumatoid arthritis. In the double-blind part of the study, patients will be randomized to receive either 162 mg tocilizumab or placebo subcutaneously every 2 weeks for 24 weeks using a pre-filled syringe. In the open-label part of the study, patients will be randomized to receive 162 mg tocilizumab subcutaneously every 2 weeks from Week 24 to Week 96 using a pre-filled syringe or an auto-injector.","primaryOutcome":{"measure":"Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24","timeFrame":"Baseline to Week 24","effectByArm":[{"arm":"Tocilizumab 162 mg sc","deltaMin":60.9,"sd":null},{"arm":"Placebo sc","deltaMin":31.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":141,"countries":["United States","Argentina","Australia","Brazil","Bulgaria","Canada","Colombia","Greece","Guatemala","Hungary","Israel","Malaysia","Mexico","New Zealand","Panama","Philippines","Poland","Russia","South Africa","Spain","Switzerland","Thailand"]},"refs":{"pmids":["24942540"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":437},"commonTop":["Alanine aminotransferase increased","Upper respiratory tract infection","Aspartate aminotransferase increased","Nasopharyngitis","Headache"]}}